GLP-1 obesity and diabetes drug development and CMO beneficiaries
For reference only. Not investment advice. You are solely responsible for your investment decisions.
6/24 · Real-time
No losers
Of 5 GLP-1 / Obesity Drug stocks tracked today, 5 are up and 0 down (avg +5.48%), an overall strongly higher tone. The top gainer is 삼성바이오로직스 (+7.62%), while 종근당 (+1.64%) lags the group.
Based on live prices and updated periodically. Not investment advice.
GLP-1 obesity and diabetes drug development and CMO beneficiaries Switch between Korean and US stock tabs below to see live prices.
Based on publicly known business structure. Not investment advice.
GLP-1 / Obesity Drug Stocks is a key investment theme in 2026. GLP-1 obesity and diabetes drug development and CMO beneficiaries PFlow tracks 15 related stocks — 7 Korean and 8 US — with live prices in one view.
There are 15 stocks related to GLP-1 / Obesity Drug Stocks — 7 Korean and 8 US stocks. Check live prices and performance in the tabs above.
PFlow's GLP-1 / Obesity Drug Stocks page (pflow.app/en/theme/glp1) shows Korean and US leading stocks with live price changes. Click any stock to view detailed data.
Korean GLP-1 / Obesity Drug Stocks stocks are 7 KOSPI/KOSDAQ-listed companies, while US GLP-1 / Obesity Drug Stocks stocks are 8 NASDAQ/NYSE-listed companies. Comparing both helps gauge global demand trends and valuation differences.
There are 15 companies related to GLP-1 / Obesity Drug — 7 Korean and 8 US. Check their live prices and leading stocks in the list above.
※ This page provides price information for companies with business connections to the listed theme. It is not a recommendation to buy or sell any specific stock. Investors are solely responsible for their investment decisions. Please conduct thorough research before investing.